Final Analysis Of A Phase II Trial Using Sorafenib For Metastatic Castration Resistant Prostate Cancer

OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer (CRPC). Secondary endpoints included pharmacokinetics, toxicity analys...

詳細記述

保存先:
書誌詳細
主要な著者: Aragon-Ching, Jeanny B., Jain, Lokesh, Gulley, James L., Arlen, Philip M., Wright, John J., Steinberg, Seth M., Draper, David, Venitz, Jürgen, Jones, Elizabeth, Chen, Clara C., Figg, William D., Dahut, William L.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2818665/
https://ncbi.nlm.nih.gov/pubmed/19154507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2008.08327.x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料